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Abstract: 
Introduction: the blood pressure, glycaemic control and electrolyte concentrations are influenced 
by autonomic nervous system and are expected to be affected by beta-2 agonist medications 
commonly used by asthmatic patients.  
Objective:The objective of this study is to detect the possible effects of beta-2 agonist medications 
on blood pressure, blood glucose and electrolytes concentrations in asthmatic patients.  
Methods: the study involved a control group of fifty-six healthy subjects matched for gender and 
age with the study group of one hundred asthmatic patients. Asthmatic patients were further 
subdivided into two according to whether they were taking beta2 agonists or not. Following verbal 
consent, blood pressures, blood glucose, sodium, potassium, calcium and magnesium 
concentrations were measured for each subject. Screening studied variables for significant 
differences in the means between the groups was performed using analysis of variance.  
Results: the diastolic blood pressure of non-asthmatic was significantly lower compared with both 
asthmatic patients not taking beta2 agonist (P = 0.036) and asthmatic patients treated by beta2 
agonist (P = 0.003). The mean of blood glucose concentration of non-asthmatic was significantly 
lower compared with the means of both asthmatic patients not taking beta2 agonist (P = 0.002) and 
asthmatic patients treated by beta2 agonist (P = 0.000). The mean of calcium concentration of non-
asthmatic was significantly lower compared asthmatic patients treated by beta2 agonist (P = 0.000) 
while the mean of magnesium concentration of asthmatic patients not taking beta2 agonist was 
significantly lower compared asthmatic patients treated by beta2 agonist (P = 0.000). Sodium and 
potassium concentrations were not significantly different among studied groups (P > 0.05).  
Conclusion: diastolic hypertension, hyperglycemia and hypercalcemia are likely to be associated 
with bronchial asthma itself, but are not because of beta2 agonist medications. However, 
hypomagnesaemia may be secondary to beta2 agonist therapy. 
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harmacologic intervention to treat 
established bronchial asthma is highly 
effective in controlling symptoms and 
improving quality of life. Approaches to 
asthma treatment in the Saudi Initiative for 
Asthma (SINA) are based on disease control 
by the utilization of Asthma Control Test for 
the initiation and adjustment of asthma 
treatment1. Asthma medications can be 
classified into controllers and relievers. 
Controllers are medications taken daily on a 
long-term basis to keep asthma under clinical 
control chiefly through their anti-
inflammatory effects. 
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 Relievers are medications used when needed 
and act quickly to reverse bronchoconstriction 
and relieve its symptoms. The most important 
relievers are rapid-acting beta-2 agonists 
while long-acting beta-2 agonists act as 
controllers. However, like other drugs, 
repeated use of beta-2 agonists is expected to 
affect many physiological parameters in the 
body. Glycaemic control and electrolyte 
concentrations are influenced by autonomic 
nervous system and are expected to be 
affected by beta-2 agonist therapy2-5. 
However, most beta2 agonist medications are 
administered through the inhalation route and 
are less likely to cause systemic 
endocrinometabolic effects6. This study aims 
to detect the possible effects of beta-2 agonist 
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medications on blood pressure, blood glucose 
and electrolytes concentrations in asthmatic 
patients. 
Materials and Methods 
The study involved two groups: a control 
group of 56 healthy subjects matched for 
gender and age with the study group of 100 
patients with a medical history of asthma but 
no other respiratory disease. Asthma history 
was recorded to assess asthma activity at the 
time of examination together with 
medications. Patients were classified into two 
according to whether they were taking beta2 
agonists or not. As other asthma medications 
were taken by both groups in a similar 
manner, they were not considered in grouping 
of patients. 
The non-invasive ausculatory method 
(Mercury in glass Sphygmomanometer – 
GOH Industries Limited - Japan) was used for 
measuring the systolic (SBP) and diastolic 
(DBP) blood pressures. Mean arterial blood 
pressure (MABP) was determined by the 
formula: MABP = DBP + [(SBP – DBP)/3]. 
Colorimetry was used for estimation of 
glucose concentrations (JENWAY 6051 
Colorimeter - Bibby Scientific Limited – 
U.K), BS-200 Chemical analyzer (Shenzhen 
Mindray Bio-Medical Electronics – China) 
for measuring calcium and magnesium 
concentrations and flame photometry was 
used for estimation of sodium and potassium 
concentrations (Flame photometer 410 - 
Sherwood Scientific Limited – U. K).  
Statistical evaluation was performed using the 
Microsoft Office Excel (Microsoft Office 
Excel for windows; 2003) and SPSS (SPSS 
for windows 17). Screening studied variables 
for significant differences in the means 
between the groups was performed using 
analysis of variance. When significant 
differences were identified, individual groups 
were compared using the Student two-tailed, 
unpaired T-test. In all of these statistical tests, 
only P < 0.05 was considered significant. 
Results 
Figure-1 compares means (M) and standard 
deviations (SD) of blood pressures of studied 
groups. The DBP of non-asthmatic (M±SD = 
75.0±10.0) was significantly lower compared 
with both asthmatic patients not taking beta2 
agonist (M±SD = 79.7±8.6) (P = 0.036) and 
asthmatic patients treated by beta2 agonist 
(M±SD = 80.4±10.7) (P = 0.003). Concerning 
SBP and MABP, they were not significantly 




Figure1: Means and standard deviations (SD) of blood pressures of studied groups 
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Figure2: Means and standard deviations (SD) of random blood glucose and sodium concentrations 





Figure3: Means and standard deviations (SD) of potassium, calcium and magnesium concentrations 
of studied groups 
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Figure-2 compares means and standard 
deviations of blood glucose and sodium 
concentrations of studied groups. The mean 
of blood glucose concentration of non-
asthmatic (M±SD = 93.6±17.1) was 
significantly lower compared with the means 
of both asthmatic patients not taking beta2 
agonist (M±SD = 103.0±11.1) (P = 0.002) 
and asthmatic patients treated by beta2 
agonist (M±SD = 103.0±10.9) (P = 0.000). 
However, the means of blood glucose 
concentration of asthmatic patients not taking 
beta2 was not significantly different when 
compared with the mean of asthmatic patients 
treated by beta2 agonist (P = 0.884). 
Figure-3 compares means and standard 
deviations of potassium, calcium and 
magnesium concentrations of studied groups. 
The mean of calcium concentration of non-
asthmatic (M±SD = 8.8±1.8) was lower, but 
was not significantly different compared with 
the mean of asthmatic patients not taking 
beta2 agonist (M±SD = 9.4±1.0) (P = 0.078), 
however, it was significantly lower compared 
asthmatic patients treated by beta2 agonist 
(M±SD = 9.8±1.1) (P = 0.000). 
The mean of magnesium concentration of 
asthmatic patients not taking beta2 agonist 
(M±SD = 1.5±0.4) was significantly lower 
compared asthmatic patients treated by beta2 
agonist (M±SD = 1.7±0.3) (P = 0.000). 
Sodium and potassium concentrations were 
not significantly different among studied 




The DBP of non-asthmatic was significantly 
lower compared with both asthmatic patients 
not taking beta2 agonist (P = 0.036). This fact 
suggests that high DBP is secondary to 
bronchial asthma itself. Stress hormones like 
cortisol and catecholamines, which may be 
increased in stressful conditions like asthma, 
are expected to increase both SBP and MABP 
alike7-9. Nevertheless, SBP and MABP were 
not significantly different among studied 
groups (P > 0.05). Therefore, a mechanism 
that predominantly increases peripheral 
vascular resistance and consequently diastolic 
blood pressure may exist to explain these 
findings10.  
Both bronchial asthma and hypertension are 
spastic disorders of smooth muscle. 
Moreover, the renin-angiotensin system was 
found to be activated in patients with asthma 
during severe acute attacks11. Angiotensin II 
is a potent vasoconstrictor, which may 
increase blood pressure in asthmatics. 
Therefore, these similarities between the 
pathophysiology of asthma and hypertension 
may predispose the patients with one disease 
to the other10,12. 
The DBP of asthmatic patients treated by 
beta2 agonist was not significantly different 
compared with those not taking beta2 agonist 
(P = 0.0491). Most beta2 agonist medications 
were administered through the inhalation 
route and are less likely to cause systemic 
endocrinometabolic effects6. The current 
study further supports this fact because DBP 
in asthmatic patients treated by beta2 agonist 
was still significantly higher when compared 
with non-asthmatic subjects (P = 0.003).  
The mean of blood glucose concentration of 
non-asthmatic subjects was significantly 
lower compared with the means of both 
asthmatic patients not taking beta2 agonist (P 
= 0.002) and those treated by beta2 agonist (P 
= 0.000) suggesting that that hyperglycemia is 
secondary to bronchial asthma itself and not 
beta2 agonist. This implication is further 
supported by the finding that the mean of 
blood glucose concentration of asthmatic 
patients not taking beta2 was not significantly 
different when compared with the mean of the 
ones treated by beta2 agonist (P = 0.884). 
Bearing in mind actions of insulin per se on 
autonomic functions i.e. diminished 
parasympathetic and enhanced sympathetic 
tones13,14, one can think of asthma activity, 
autonomic balance, hyperglycemia secondary 
to insulin resistance to be closely connected. 
Importantly, insulin resistance is associated 
with aeroallergen sensitization and allergic 
asthma, but not non-allergic asthma15. 
Furthermore, Al-Shawwa et al hypothesize 
that the pro-inflammatory state of insulin 
resistance may contribute to the pathogenesis 
of asthma in obese patients16. In addition, 
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insulin sensitivity was increased in asthmatic 
patients as a result of improvements in 
respiratory function noted following proper 
treatment2. Based on these studies and 
findings of present study, insulin resistance 
may explain hyperglycemia associated with 
bronchial asthma. 
The mean of calcium concentration of non-
asthmatic was significantly lower compared 
with those treated by beta2 agonist (P = 
0.000). On the other hand, the mean of 
magnesium concentration of asthmatic 
patients not taking beta2 agonist was 
significantly lower compared with those 
treated by beta2 agonist (P = 0.000). Sodium 
and potassium concentrations were not 
significantly different among studied groups 
(P > 0.05).  
Most previous studies on electrolyte 
disturbance in asthmatics have focused on 
asthma treatment as a contributing factor4,17-
19. 
IV ß2-agonists
 cause an increase in the urinary 
excretion of calcium17. This is also true in 
patients treated with IV aminophylline18. The 
findings of this study did not contradict 
previous studies, as none of asthmatic patients 
were receiving IV ß2-agonists or IV 
aminophylline during the measurement of 
their electrolytes concentrations. On the other 
hand, studies of asthma patients indicate that 
dietary magnesium intake and serum 
magnesium levels are lower than healthy 
controls20. High magnesium intake was 
associated with improvement in symptom 
scores, though not in measures of airflow or 
airway reactivity21. The mechanisms for 
effects of magnesium on lung function 
include alteration in smooth muscle 
function22, immune function23 and oxidative 
stress. When magnesium is deficient, the 
action of calcium is enhanced and an excess 
of magnesium blocks calcium. These 
interactions are important to the respiratory 
patient because the intracellular influx of 
calcium causes bronchial smooth-muscle 
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